Pulmatrix, Inc.

FRAMINGHAM, MA · Founded 2013 · Biotech · Public

Pulmonary-delivered therapeutic formulations using iSPERSE™ inhalation technology platform

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · pulmatrix.com

Sector: Biotech
Headquarters: FRAMINGHAM, MA
Founded: 2013
Latest Form D: $1M, Apr 2026
Total capital: $41M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $41M; 14 Form D · last Apr 2026; 6 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 4; 33 pending · first 2015; Rank in peer group#293 of 1449

Capital timeline

Latest events

Apr 2026Private capital raisedForm D · SEC · 14th filing$1M
Jul 2021Private capital raisedForm D · SEC · 13th filing$45K
Feb 2021Offering registeredForm D · SEC · 12th filing$3.3M
Jul 2020Offering registeredForm D · SEC · 11th filing$19.6M
Apr 2020Private capital raisedForm D · SEC · 10th filing$8.1M
Feb 2019Private capital raisedForm D · SEC · 9th filing$22K
Feb 2019Private capital raisedForm D · SEC · 8th filing$2.5M
Feb 2019Private capital raisedForm D · SEC · 7th filing$74K
Dec 2018Private capital raisedForm D · SEC · 6th filing$3.7M
Jun 2015Private capital raisedForm D · SEC · 5th filing$935K
Jun 2015Private capital raisedForm D · SEC · 4th filing$688K
Jun 2015Private capital raisedForm D · SEC · 3rd filing$21.4M
Jun 2015Offering registeredForm D · SEC · 2nd filing$210K
Jun 2015Private capital raisedForm D · SEC · 1st filing$2.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#293 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Amit MunshiDirectorNamed in SEC Form D filings
Anand VaradanDirectorNamed in SEC Form D filings
Christopher D. CabellDirectorNamed in SEC Form D filings
David T EdwardsDirectorNamed in SEC Form D filings
David HavaExecutive OfficerNamed in SEC Form D filings
David MakiDirectorNamed in SEC Form D filings

Show all 30 people

Gregory FrenchDirector, PromoterNamed in SEC Form D filings
Hojabr AlimiExecutive Officer, PromoterNamed in SEC Form D filings
James RoachExecutive OfficerNamed in SEC Form D filings
Kurt GravesDirectorNamed in SEC Form D filings
Lauren T. SilvermanDirectorNamed in SEC Form D filings
Mark T GabrielsonDirectorNamed in SEC Form D filings
Mark IwickiDirectorNamed in SEC Form D filings
Matthew ShermanDirectorNamed in SEC Form D filings
Michael HigginsDirectorNamed in SEC Form D filings
Michelle S. SiegertExecutive OfficerNamed in SEC Form D filings
. Oculus Innovative Sciences, Inc.PromoterNamed in SEC Form D filings
Peter LudlumExecutive OfficerNamed in SEC Form D filings
Richard J. BatyckyDirectorNamed in SEC Form D filings
Richard ConleyDirector, PromoterNamed in SEC Form D filings
Robert ClarkeExecutive Officer, DirectorNamed in SEC Form D filings
Robert T. ConnellyDirectorNamed in SEC Form D filings
Sameer HarishExecutive Officer, PromoterNamed in SEC Form D filings
Scott T RocklageDirectorNamed in SEC Form D filings
Steven T GillisDirectorNamed in SEC Form D filings
Teofilo RaadExecutive OfficerNamed in SEC Form D filings
Terrance McGuireDirectorNamed in SEC Form D filings
Terry T McGuireDirectorNamed in SEC Form D filings
Todd J. BazemoreDirectorNamed in SEC Form D filings
William DukeExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 37

Aug 22, 2017GrantedTiotropium Dry PowdersUSPTOUS 9,737,518
Jan 12, 2016GrantedDry Powder Formulations And Methods For Treating Pulmonary DiseasesUSPTOUS 9,233,158
Sep 1, 2015GrantedDry Powder Formulations And Methods For Treating Pulmonary DiseasesUSPTOUS 9,119,778

Show all 37 patent records

Tiotropium Dry PowdersAug 22, 2017 · US 9,737,518Granted
Dry Powder Formulations And Methods For Treating Pulmonary DiseasesJan 12, 2016 · US 9,233,158Granted
Dry Powder Formulations And Methods For Treating Pulmonary DiseasesSep 1, 2015 · US 9,119,778Granted
Monovalent Metal Cation Dry Powders For InhalationAug 20, 2015 · Application 14666959Pending
Respirably Dry Powder Comprising Calcium Lactate, Sodium Chloride And LeucineJul 23, 2015 · Application 14633432Pending
Formulations For Alteration Of Biophysical Properties Of Mucosal LiningJul 16, 2015 · Application 14541648Pending
Inhalable Dry PowdersMay 21, 2015 · Application 14378453Pending
Respirably Dry Powder Comprising Calcium Lactate, Sodium Chloride And LeucineMar 31, 2015 · US 8,992,983Granted
Formulations Decreasing Particle ExhalationMar 19, 2015 · Application 14058852Pending
Methods For Treating And Diagnosing Respiratory Tract InfectionsNov 13, 2014 · Application 14350235Pending
Pharmaceutical Formulations And Methods For Treating Respiratory Tract InfectionsMay 15, 2014 · Application 14061006Pending
Monovalent Metal Cation Dry PowdersApplication PCTUS2011053829Pending
Cationic Dry PowdersApplication PCTUS2011053833Pending
Calcium Lactate Dry PowdersApplication PCTUS2011049333Pending
Methods For Treating Cystic FibrosisApplication PCTUS2011049342Pending
Dry Powder Formulations And Methods For Treating Pulmonary DiseasesApplication PCTUS2011049435Pending
Use Of Trp Channel Agonists To Treat InfectionsApplication PCTUS2011044628Pending
Pharmaceutical Formulations And Methods For Treating Respiratory Tract InfectionsApplication PCTUS2010028906Pending
Calcium Citrate And Calcium Lactate Formulations For Alteration Of Biophysical Properties Of Mucosal LiningApplication PCTUS2010028914Pending
Anti-influenza Formulations And MethodsApplication PCTUS2010028900Pending
Methods For Treating And Preventing Pneumonia And Ventilator-associated TracheobronchitisApplication PCTUS2010028901Pending
Dry Powder Formulations And Methods For Treating Pulmonary DiseasesApplication PCTUS2010028961Pending
Diagnostic Device For Determining Particle ProductionApplication PCTUS2007008815Pending
Formulations For Alteration Of Biophysical Properties Of Mucosal LiningApplication PCTUS2006019443Pending
Ultrasonic Aerosol GeneratorApplication PCTUS2006017248Pending
Method And Device For Decreasing ContaminationApplication PCTUS2006000618Pending
Formulations Decreasing Particle ExhalationApplication PCTUS2005006903Pending
Acid Content Addition To Tiotropium Containing Dry PowdersApplication 62061436Pending
Stability Of Tiotropium Containing Dry Powder FormulationsApplication 62061433Pending
Dry Powder Formulations And Methods For Treating Pulmonary DiseasesApplication 14456445Pending
Formulations For Alteration Of Biophysical Properties Of Mucosal LiningApplication 14450753Pending
Formulations For Alteration Of Biophysical Properties Of Mucosal LiningApplication 14208695Pending
Tiotropium Dry PowdersApplication PCTUS2014025660Pending
Tiotropium Dry PowdersApplication 61925400Pending
Processable Dry PowdersApplication PCTUS2013028261Pending
Methods For Treating And Diagnosing Respiratory Tract InfectionsApplication PCTUS2012059022Pending
Methods Of Treating And Preventing Rhinovirus InfectionApplication PCTUS2011059330Pending

ADMA PLASMA BIOLOGICS, INC.Similar federal contract value in Biotech · null in contracts
Pahr Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Achelios Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
ImmunoVec, Inc.Similar federal contract value in Biotech · null in contracts
Aurinia Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
Indi Molecular, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.